新型血液檢測技術有望早期發現50種癌症
New blood test could detect 50 types of cancer early
醫學正在取得長足進步，Galleri檢測的開發即是一項突破，該項檢測旨在透過單一血液樣本偵測超過50種癌症。
Medical science is making strides with the development of the Galleri test, a breakthrough designed to detect over 50 types of cancer from a single blood sample.
這項創新工具藉由分析無細胞DNA及其甲基化模式，尋找顯示疾病存在的化學標記。
By analyzing cell-free DNA and its methylation patterns, this innovative tool looks for chemical markers that indicate the presence of disease.
該檢測由GRAIL公司研發，主要針對50歲以上或患癌風險較高的成年人。
Developed by GRAIL, the test is specifically aimed at adults over 50 or those at higher risk.
盡管該技術展現了高達99.5%的特異度，但必須瞭解的是，它是一種篩檢工具，而非診斷工具。
While the technology shows a remarkable 99.5% specificity, it is important to understand that it is a screening tool, not a diagnostic one.
目前，該檢測尚未獲得美國食藥署(FDA)批准，且其對長期存活率的影響正在大型臨床試驗中進行評估。
Currently, the test has not been approved by the FDA, and its impact on long-term survival rates is still being evaluated in large clinical trials.
患者應知悉檢測結果並非定論；呈陽性反應需要進一步的影像學檢查和切片檢查以確診，而陰性結果亦不保證未患癌症。
Patients should be aware that results are not definitive; a positive signal requires follow-up imaging and biopsies to confirm a diagnosis, while a negative result does not guarantee the absence of cancer.
隨著研究人員持續探討其臨床實用性，Galleri檢測代表了現代醫療技術中一項令人興奮且深具探索性的進展。
As researchers continue to study its clinical utility, the Galleri test represents an exciting, albeit investigative, step forward in modern healthcare technology.
